Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
DIABETOLOGY & METABOLIC SYNDROME, vol.10, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 10
- Publication Date: 2018
- Doi Number: 10.1186/s13098-018-0331-8
- Journal Name: DIABETOLOGY & METABOLIC SYNDROME
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Keywords: Type 2 diabetes, Gliclazide, Glycemic control, Tolerability, Real-world, CARDIOVASCULAR OUTCOMES, RAMADAN, HYPOGLYCEMIA, EMPAGLIFLOZIN, SULFONYLUREA, SAXAGLIPTIN, SITAGLIPTIN, MORTALITY
- Istanbul University Affiliated: Yes
Abstract
Background: Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment.